Stockscreener 앱 받기
13.34
7.93%
0.98
시간 외 거래:
13.34
Evommune Inc 주식(EVMN)의 최신 뉴스
Evommune, Inc. (EVMN) Securities Fraud InvestigationLevi & Korsinsky - Morningstar
Stifel Maintains Evommune(EVMN.US) With Buy Rating, Maintains Target Price $54 - Moomoo
Top 3 Health Care Stocks That May Rocket Higher In July - Benzinga
EVMNEvommune Inc Options - Finviz
Evommune, Inc. (NYSE: EVMN) Stock Price, News & Analysis - Kalkine
This Biotech Stock Nearly Doubled In Value Today Morning – What’s Driving Investor Optimism? - Stocktwits
Evommune’s EVO756 Trial Completion Signals Key Milestone in Chronic Urticaria Market - TipRanks
Evommune’s Healthy Balance Sheet Buys Them Time For AD (NYSE:EVMN) - Seeking Alpha
Evommune drops on phase 2 data for EVO756 in urticaria - MSN
Oral CSU Drug Falls Short in Phase 2b Study; Evommune Ends Development - The Dermatology Digest
Evommune shares plunge 38% after lead drug fails Phase 2b trial; insiders sold shares days before news. - Pluang
Evommune, Inc. Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Evommune, Inc. (EVMN) - PR Newswire
EVMN Stock Tanks as Phase IIb Urticaria Study Misses Primary Goal - The Globe and Mail
Evommune stock downgraded by H.C. Wainwright after trial failure - Investing.com South Africa
EVMN Maintained by Morgan Stanley -- Price Target Lowered to $26 - GuruFocus
Morgan Stanley Maintains Evommune(EVMN.US) With Buy Rating, Cuts Target Price to $26 - Moomoo
Evommune Inc : RBC Cuts Target Price to $30 F - Moomoo
A Quick Look at Today's Ratings for Evommune(EVMN.US), With a Forecast Between $26 to $28 - Moomoo
This AAR Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Tuesday - Benzinga
Evommune ends development of lead asset in chronic hives after mid-stage efficacy woes - BioSpace
HC Wainwright Downgrades Evommune to Neutral From Buy - marketscreener.com
Evommune drops EVO756 in CSU after Phase IIb failure - The Pharma Letter
Evommune terminates oral drug’s development in CSU - Clinical Trials Arena
Evommune (EVO) Faces Setback as EVO756 Fails Key Trial for Chron - GuruFocus
Sectoral Asset Management Inc's Evommune Inc(EVMN) Holding History - GuruFocus
Evommune shares slide after phase 2b CSU trial misses main goal (EVMN) - MSN
Evommune, Inc. Stock 12‑Month Price Target Cut to $39.33, Implies 56% Upside - TradingView
EVMN Downgraded by William Blair -- Rating Changed to Market Per - GuruFocus
Evommune Still Has Shot At Atopic Dermatitis With EVO756 After Urticaria Failure - insights.citeline.com
Evommune stock rating cut to Market Perform by William Blair - Investing.com UK
Less than a year after IPO, Evommune stock is getting pummeled — here's why - The Business Journals
Evommune, Inc.(NYSE: EVMN) dropped from Russell Small Cap Comp Value Benchmark - marketscreener.com
Evommune, Inc.(NYSE: EVMN) dropped from Russell Microcap Value Benchmark Index - marketscreener.com
Evommune, Inc.(NYSE: EVMN) dropped from Russell 3000E Value Benchmark - marketscreener.com
Why is Evommune stock plummeting today? By Investing.com - Investing.com India
Evommune, Inc.(NYSE: EVMN) dropped from Russell 2500 Value Benchmark - marketscreener.com
Evommune, Inc.(NYSE: EVMN) dropped from Russell 2000 Value Benchmark - marketscreener.com
Evommune's EVO756 Misses Primary End Point in Phase 2b CSU Trial, Development Continues in AD and Migraine - Dermatology Times
Why is Evommune stock plummeting today? - Investing.com UK
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Evommune's Skin Disorder Study Falls Short - Benzinga
Evommune slips as oral drug fails mid-stage urticaria study - FirstWord Pharma
Evommune’s EVO756 Fails Phase 2b in Chronic Spontaneous Urticaria but Advances in Atopic Dermatitis and Migraine Trials – Minichart - Minichart
Evommune (EVMN) Reports Phase 2b Trial Results for EVO756 - GuruFocus
Raymond James cuts Evommune stock rating on trial miss By Investing.com - Investing.com Nigeria
Raymond James cuts Evommune stock rating on trial miss - Investing.com
1.17%
2.48%
자본화:
|
볼륨(24시간):